Skip to main content
PLOS One logoLink to PLOS One
. 2021 Jul 1;16(7):e0253912. doi: 10.1371/journal.pone.0253912

PKCδ deficiency inhibits fetal development and is associated with heart elastic fiber hyperplasia and lung inflammation in adult PKCδ knockout mice

Yuko S Niino 1,¤a, Ikuo Kawashima 2, Yoshinobu Iguchi 3, Hiroaki Kanda 4, Kiyoshi Ogura 2, Kaoru Mita-Yoshida 5, Tomio Ono 5, Maya Yamazaki 6,¤b, Kenji Sakimura 6,¤c, Satomi Yogosawa 7, Kiyotsugu Yoshida 7, Seiji Shioda 1,¤d, Takaya Gotoh 8,*
Editor: Diego Fraidenraich9
PMCID: PMC8248728  PMID: 34197550

Abstract

Protein kinase C-delta (PKCδ) has a caspase-3 recognition sequence in its structure, suggesting its involvement in apoptosis. In addition, PKCδ was recently reported to function as an anti-cancer factor. The generation of a PKCδ knockout mouse model indicated that PKCδ plays a role in B cell homeostasis. However, the Pkcrd gene, which is regulated through complex transcription, produces multiple proteins via alternative splicing. Since gene mutations can result in the loss of function of molecular species required for each tissue, in the present study, conditional PKCδ knockout mice lacking PKCδI, II, IV, V, VI, and VII were generated to enable tissue-specific deletion of PKCδ using a suitable Cre mouse. We generated PKCδ-null mice that lacked whole-body expression of PKCδ. PKCδ+/- parental mice gave birth to only 3.4% PKCδ-/- offsprings that deviated significantly from the expected Mendelian ratio (χ2(2) = 101.7, P < 0.001). Examination of mice on embryonic day 11.5 (E11.5) showed the proportion of PKCδ-/- mice implanted in the uterus in accordance with Mendelian rules; however, approximately 70% of the fetuses did not survive at E11.5. PKCδ-/- mice that survived until adulthood showed enlarged spleens, with some having cardiac and pulmonary abnormalities. Our findings suggest that the lack of PKCδ may have harmful effects on fetal development, and heart and lung functions after birth. Furthermore, our study provides a reference for future studies on PKCδ deficient mice that would elucidate the effects of the multiple protein variants in mice and decipher the roles of PKCδ in various diseases.

Introduction

Protein kinase C (PKC) is a phospholipid-dependent serine/threonine kinase, first identified in 1977 by Nishizuka et al., and it plays critical roles in intracellular signal transduction [13]. Mammalian PKCs form a large family, categorized based on their molecular structures and activation mechanisms as conventional PKC (cPKC), requiring calcium, phosphatidylserine, and diacylglycerol for activation (α, β, and γ isoforms); novel PKC (nPKC), which do not require calcium for activation (δ, ε, η, and θ isoforms); and atypical PKC, which do not require calcium or diacylglycerol for activation (ζ and λ/i isoforms). PKCδ belongs to the nPKC family, and PKCδI was the first PKCδ molecular species to be reported. PKCδI is expressed ubiquitously in various tissues and cells, suggesting a general role rather than a tissue- or cell-specific function [4]. PKCδ is involved in many cellular processes [5,6], including cell growth [7], apoptosis [8,9], tumor inhibition [10], and cell migration [11]. cPKCs and nPKCs, including PKCδ, are activated by the oncogenic promoter phorbol 12-myristate 13-acetate and, hence, are considered as drivers of tumorigenesis [4]. However, despite over 30 years of clinical trials investigating PKC inhibitors as anti-cancer agents, PKC inhibitors have failed to show tumor-suppressive effects and, in some cases, have worsened symptoms [12]. Detailed studies have identified PKCδ as a tumor suppressor [13]. Additionally, PKCδ has a caspase-3 cleavage sequence, called the DILD motif, in its V3 domain, indicating a role in apoptosis [6,7,1416].

Studies based on PKCδ knockout mice (PKCδ KO) have demonstrated that PKCδ is involved in the maintenance of smooth muscle homeostasis and that PKCδ KO mice develop normally and are fertile [17]. PKCδ plays a critical role in B cell homeostasis and tolerance, highlighting its potential role in the treatment of autoimmune diseases [18,19]. Although these studies reported significant findings, the PKCδ KO mice used in these studies lacked only the PKCδI and δII isoforms. Studies have shown that several PKCδ isoforms are generated by the alternative splicing from single PKCδ gene (Prkcd), and that PKCδ itself forms a family (Fig 1). To date, the expression levels of PKCδI, II, IV, V, VI, VII, and IX have been reported in mice [2022], those of PKCδI and III in rats [23], and those of PKCδI and VIII in humans [24]. In mice, caspase-3 recognition sequences are present in PKCδI, IV, and VI. PKCδII, V, and VII have a 78-bp insertion sequence with no frameshift in the DILD motif; therefore, PKCδII, V, and VII are not cleaved by caspase-3 [21]. PKCδVIII, the human homolog of the mouse PKCδII [24], exerts anti-apoptotic effects in NT2 cells [25,26]. Moreover, insulin enhances cell growth by further promoting alternative splicing of PKCδII in HT22 cells [27]. It has been suggested that the PKCδ variants may have distinct functions.

Fig 1. Schematic structures of mouse protein kinase C delta (PKCδ) isoforms and genomic DNA.

Fig 1

(A) PKCδI and II cDNAs consist of variable domains V1, V2, V3, V4, and V5, and conserved domains C2-like, C1a, C1b, C3, and C4. The C1 regulatory domain contains two cysteine-rich zinc finger motifs. PKCδIV, V, VI, and VII consist of C1a, C1b, V3, C3/V4/C4, and V5 domains. Dark blue, DILD caspase-3 recognition site; light blue, 78 bp insertion in DILD caspase-3 recognition site; and yellow, specific exon for PKCδVI and VII [2022]. (B) Schematic structure of the PKCδ genome.

Exons are indicated by orange, red, light blue, and yellow boxes and numbered according to a report on the mouse genome by Suh et al. [28]. Red, exon 4a; blue, 78 bp insertion in the caspase-3 recognition site; yellow, specific exon for PKCδVI and VII; M, the first methionine; and asterisks, the termination codon. Introns are shown with horizontal lines. PKCδ isoform-characteristic exons are shown under the schematic structures of the entire PKCδ genomic DNA.

The complex regulation of gene transcription and the production of multiple splice variants, each with their own functions, indicates the efficiency of gene usage. However, mutations at key points in a gene can result in the simultaneous loss of multiple proteins. In the present study, we generated mice with comprehensive deletion of the PKCδ-encoding gene, to elucidate the functions of PKCδ. Thus, in this study, a new PKCδ-deficient mouse model was generated by deleting the exon shared by PKCδI, II, IV, V, VI, and VII. We report that this mouse model yielded different data than what has been previously described.

Materials and methods

Mouse breeding

All mice procedures were carried out in accordance with the guidelines laid down by the Institutional Animal Care and Use Committees and the Ethics Committees of Tokyo Metropolitan Institute of Medical Science (approval number 15085, 16018, 17026, 18010), Niigata University (approval number SA00542), and Showa University (approval number 50040, 51014, 52016) approved this study.

Generation of PKCδ-flox mice

Three genomic DNA fragments of the PKCδ gene (Prkcd): 4.6 kb of the 5′ arm, 0.85 kb of the region including exon 7, and 6 kb of the 3′ arm were amplified using polymerase chain reaction (PCR) from the mouse genomic bacterial artificial chromosome RP23-283B12 (Thermo Fisher Scientific, Waltham, Massachusetts, USA). The targeting vector contained the 5′ arm gene fragment upstream of the first loxP sequence, pgk-1 promoter-driven neomycin phosphotransferase gene, and exon 7 (86 bp) of the PKCδ gene downstream of the first loxP sequence, with the 3′ arm gene fragment downstream of the second loxP sequence. Additionally, the targeting vector contained a diphtheria toxin gene for negative selection (Fig 2A), and was electroporated into the C57BL/6N-derived embryonic stem (ES) cell line, RENKA [29], after linearization by SalI digestion. Homologous recombinants were identified by Southern blotting. After digestion with EcoRI and BamHI, the genomic DNA samples were hybridized with 5′- and 3′-probes, as shown in Fig 2A. DNA was separated on a 0.6% agarose gel, followed by transfer to a Biodyne Plus membrane (Pall Corp., New York, USA). The membrane was hybridized with DNA probes labeled with the PCR DIG probe synthesis kit (Roche, Basel, Switzerland). The probes were detected with an alkaline phosphatase-conjugated anti-DIG antibody and visualized with a DIG luminescent detection kit (Roche). EcoRI digested genomic DNA hybridized with a 5′-probe showed 10.3 kb for wild type (WT) and 8.2 kb for the targeted allele. BamHI digested genomic DNA hybridized with the 3′-probe showed 16.6 kb for the WT allele and 15.4 kb for the targeted allele (Fig 2B). ES cells with the correct recombination were used to produce chimeric mice.

Fig 2. Generation of protein kinase C delta (PKCδ)-deficient mice.

Fig 2

(A) Schematic representation of murine Prkcd genes, targeting vectors, targeted allele, and knockout allele. Numbers denote the exon numbers, and light blue boxes denote 5ʹ- and 3ʹ- probes for Southern blotting. Polymerase chain reaction (PCR) primers for genotyping are indicated by arrows. Red letters E and B represent EcoRI and BamHI, respectively. Dashed line indicates vector sequence. (B) Southern blotting using genomic DNA of wild type (WT) and flox+/flox+ mouse. DNA digested using EcoRI was used for 5′-probes and shows sizes of 10.3 KB for WT and 8.3 kb for flox+/flox+ mice. DNA digested using BamHI was used for 3′-probes and shows sizes of 16.6 kb for WT and 15.4 kb for flox+/flox+ mice. (C) Genotypic analysis by PCR. PCR analysis was performed using genomic DNA extracted from 4-week-old mice tails and the amniotic membranes of fetuses. WT shows bands of 1078 bp, KO of 315 bp, and He of both 1078 and 315 bp.

Generation of PKCδ deficient mice

PGK2-Cre mice [Tg (Pgk2-cre) 24Shb] [30] maintained at Showa University, specifically express Cre recombinase in spermatocytes, and were used for mating with the PKCδ-flox mice to obtain PKCδ-deficient mice. From the offsprings, we selected PKCδ+/- (He, hetero-type knockout) and Cre-/- mice and mated them to obtain homozygous PKCδ-/- mice (KO, PKCδ knockout).

Genotyping PKCδ deficient mice using PCR

Genotyping was performed by PCR using genomic DNA from the tail of 4-week-old offsprings, and the amnion from the embryos using the Tks Gflex DNA polymerase (TAKARA, Kusatsu, Shiga, Japan) under the following conditions: 2 min at 94°C, 35 cycles of 20 sec at 94°C, 1 min at 68°C, followed by 2 min at 68°C. The primers used for genotyping are given in Fig 2, and their sequences are as follows: forward, 5′-GCAGGTGGTGAGTGTTCCTT-3′; reverse, 5′-GGCATGTCGATGTTGAAGCG-3′. The size of the PCR products was 1078 bp for WT and 315 bp for KO allele.

Histological analysis

Hearts, lungs, and spleens were removed from WT (PKCδ+/+) and KO mice at 16 and 24 weeks of age for histological analysis. After mating 11 pairs of PKCδ He mice, E11.5 embryos were collected after confirming the number of embryo sacs. Genomic DNA from the amniotic membranes from E11.5 was used for fetal genotyping. Murine tissues and E11.5 embryos were fixed using 4% paraformaldehyde solution at 4°C overnight, dehydrated, defatted through an ethanol- and xylene-series, and then paraffin-embedded. Each tissue was sliced into 5-μm thick sections and stained with Hematoxylin and Eosin (H&E stain). The heart and lung sections were stained using Masson’s trichrome (MT) and Elastica van Gieson staining (EVG) to stain collagen fibers and elastic fibers, respectively. We used Hematoxylin solution made by Muto Pure Chemicals Co. Ltd. (Tokyo) and Eosin solution by Sakura Finetek Japan Co. Ltd. (Tokyo). For both MT and EVG, we used staining solutions made by Muto Pure Chemicals Co. Ltd. (Tokyo).

Statistical analysis

The statistical difference between our results and Mendel’s law was analyzed using the chi-square test. The Kaplan–Meier method was used to analyze the survival of PKCδ KO mice.

Results

Generation of PKCδ-deficient mice

In the present study, PKCδ-deficient mice were generated to analyze the function of PKCδ. PKCδ is reported to generate eight molecular species (PKCδI, II, IV, V, VI, VII, and IX) from a single gene (Prkcd) in mice [2022]. The structures of the mouse PKCδ molecular species in mice are shown in Fig 1A. Studies on PKCδ knockout mice (KO) reported that KO mice were not deficient in all PKCδ molecular species [17,18]. Therefore, to fix the lineage of PKCδ knockout mice into C57BL6/N mice, we generated conditional knockout C57BL6/N mice with deficient PKCδI, II, IV, V, VI, and VII using the RENKA, C57BL/6N ES cell line.

The relationship between the PKCδ gene structure and the different molecular species generated by alternative splicing is shown in Fig 1B, with the genetic architecture previously described by Suh et al. [28]. In the present study, we inserted LoxP sequences in the upstream and downstream regions of exon 7 of 86 base pairs, that could reliably frameshift due to the defect and prevent protein generation (Fig 2A). Homologous recombination was performed using the RENKA C57BL/6N ES cell line [29] to generate PKCδ conditional knockout mice (PKCδ flox/+). PKCδ flox/flox mice were further generated by self-mating PKCδ flox/+ mice, which were then enrolled (registered: C57BL/6 Prkcd<tm1Shb>). Confirmation of this genetic insertion of PKCδflox/ flox mice was performed by genomic Southern blotting with C57BL/6N wild-type mice (Fig 2B). PKCδ flox mice were crossed with PGK2–Cre mice [Tg (Pgk2-cre) 24Shb] [30] to generate conditional knockout of PKCδ genes (PKCδ KO). Since PGK2–Cre mice express Cre recombinase in spermatocytes and spermatids in the testis, the resulting male mice have a PKCδ gene deletion in their spermatozoa. PKCδ+/- mice with Cre-/- genotypes obtained by crossing with wild-type PKCδ+/+ (WT) were enrolled as PKCδ+/-, which means PKCδ gene Heterozygous mice (He) (registered: C57BL/6-Prkcd<tm1. 1Shb>).

Male and female PKCδ He mice were mated, offspring were weaned four weeks after delivery, and the genotypes were confirmed using PCR. Representative PCR data are shown in Fig 2C. The genotypes of the resulting offspring at weaning are indicated in Table 1. The proportion of genotypes in the offspring mice was expected to be WT:He:KO = 1:2:1, whereas the observed proportion was WT:He:KO = 104 (27.1%):267 (69.5%):13 (3.4%). The genotypes of all 384 offspring born from pairs of PKCδ He mice did not follow Mendelian rules (By χ2 test, χ2 = 101.7, p< 0.001).

Table 1. Genotypic analysis of 4-week-old offspring mice at weaning from heterozygous parents.

WT He KO
Male 53 144 3
Female 51 123 10
Total 104 267 13
Rate of offspring 27.1% 69.5% 3.4%

The genotypes of all 384 offspring born from pairs of PKCδ. He mice did not follow Mendelian rules (χ2(2) = 101.7, p < 0.001).

Genotypes: WT, wild type mice; He, hetero-type knockout mice; KO, homozygous PKCδ-/- mice (PKCδ knockout).

The lifespan of all PKCδ KO mice born to pairs of PKCδ He mice was as follows: 2.5 months (n = 1), 3 months (n = 2), 6 months (n = 1), 7 months (n = 1), 11 months (n = 2), 13 months (n = 1), and 15 months (n = 1). Four other knockout mice were used in the experiment. These nine PKCδ KO mice were kept simultaneously with their littermate WT and He mice, and their Kaplan-Meier survival curves are shown in Fig 3. However, since WT and He mice were euthanized at 1 year (52 weeks old), the study by Yuan R. et al. [31] was cited as supplementary data for WT. No spontaneous death was observed in WT and He mice within 1 year. In contrast, KO mice started to die when they were 10 weeks old. As a result, it was found that the 50% survival rate of the KO mice was 31.8 weeks, which was 1/4 that of WT mice.

Fig 3. Survival curve of PKCδ KO mice (Kaplan-Meier plots).

Fig 3

PKCδ He mice were spontaneously bred, the genotypes of the offsprings were determined, and their survival was monitored. KO mice (all nine KO mice) were observed until all mice died, whereas WT and He mice were euthanized at 52 weeks of age. Therefore, the study by Yuan et al. [31] is cited as supplementary data for WT and is indicated by the dashed arrow.

Histological analysis

Eight mice were euthanized for histological analysis. Four PKCδ KO mice (one male and two female 24-week-old mice, one male 16-week-old mouse), and four gender- and age-matched WT mice descend from a pair of PKCδ He parents. Visual observations revealed that all PKCδ KO mice had enlarged spleens compared to those of PKCδ WT mice, and the hearts were enlarged in three of the four PKCδ KO mice (Fig 4A). Additionally, conspicuous deformation was observed in the lungs of three out of four KO mice (Fig 4A). These findings are summarized in Table 2. No visible differences were observed in the other organs. Histological analysis was performed for each of the above organs. Calcification was observed in the heart of two out of four PKCδ KO mice, and inflammation was observed in the lungs of three out of four KO mice, indicating poorly air space, as observed by H&E staining (Fig 4B). In the two cases with a cardiac abnormality, a calcific mass above the left ventricle in one mouse (Fig 4B and 4C) and calcification was observed at the base of the cardiac mitral valve in the other mouse (Fig 4D) were observed. The calcification in both cases observed in the hearts of male mice. MT and EVG staining were performed on heart sections of mice with calcification in the heart to examine the reason for the calcification. In MT staining, collagen fibers were stained blue with aniline blue solution and the cytoplasm was stained red with Masson’s solution. In EVG staining, elastic fibers were stained black with resorcinol fuchsin solution, collagen fibers were stained red with Sirius red solution, and muscle fibers were stained yellow with picric acid. The staining indicated a clear increase in elastic fibers in the hearts of PKCδ KO mice compared to the hearts of WT mice (Fig 5A). In both PKCδ KO mice hearts, EVG staining revealed that there was a hyperplasia of the elastic fibers in the endocardium. In addition, there was a slight trend in the blood vessels of the heart. Furthermore, the results of MT staining showed an increase in collagen fibers; however, the changes in elastic fibers were more intense and predominant. This may have resulted in lime-induced thrombus; however, a causal relationship could not be established. An increase and calcification of elastic fibers in the endocardium were observed in the hearts of two of the four PKCδ KO mice. However, it was difficult to determine whether this change was significant. In addition, MT and EVG staining were performed on the hearts of PKCδ KO mice without cardiac enlargement and there was no difference was observed compared to the WT mice. Examination of lung abnormalities revealed that three PKCδ KO animals showed more eosinophilic exudates and macrophages in the alveoli, and more round cell infiltrates compared with those of the PKCδ WT mice. Macrophages were also found in the bronchi. Despite strong congestion and inflammation in the lungs, the increase in fiber was inconspicuous. Lung abnormalities appeared to be a change resulting from decreased cardiac function (Fig 5B).

Fig 4. Histological analysis of WT and KO mice.

Fig 4

(A) Comparison of heart and spleen sizes between WT and KO mice. Arrow indicates the site of deformity in the lung. Scale bars represent 2 mm. (B) Hematoxylin and eosin-stained images of hearts, lungs, and spleens from WT and KO mice. The heart image shows a cross-section. Scale bars represent 1 mm for the heart and spleen and 200 μm for the lung. Arrow indicates the site of calcification. (C) Heart of a KO mouse with internal calcification. Arrow indicates the site of calcification. (D) Hematoxylin and eosin-stained images of vertically cut hearts from KO mice. Inset shows calcification at the base of the mitral valve. Scale bars represent 1 mm. Arrow indicates the site of calcification.

Table 2. Phenotypic analysis of KO-mice.

Age Sex Heart Lung Spleen
Enlarged Calcification Inflammation Enlarged
1 16 w Male + + + +
2 24 w Male + + + +
3 24 w Female + - + +
4 24 w Female - - - +

Age, sex, and phenotype of the mice (n = 4) subjected to histological analysis are shown.

Fig 5. Images of elastic fiber staining of hearts from WT and KO mice.

Fig 5

(A) Elastica van Gieson (EVG) and Masson’s trichrome (MT) staining were performed using horizontally cut hearts from WT and KO mice. An enlarged view is shown on the right. Scale bars represent 1 mm. Arrow indicates the site of calcification. (B) EVG and MT staining images of lungs from WT and KO mice. An enlarged view is shown on the right. Scale bars represent 500 μm.

Analysis of 11.5-day-old embryos

To verify the reason for the low production rate of approximately 3.4% of PKCδ KO mice from crosses between PKCδ He mice, we analyzed fetuses on embryonic day 11.5 (E11.5). PKCδ He mice were self-crossed, and 11 pregnant mice were examined. The uterus was removed, and the fetus was collected after confirming the number of fetal sacs. The total number of fetal sacs was 104, and 103 fetuses were identified. One fetal sac contained no fetus, as it had already been resorbed. The fetal implantation rate of each genotype is shown in Table 3A. Genotypes were determined by PCR using genomic DNA from the amniotic membrane. The PCR patterns of WT, He, and KO mice are shown in Fig 2C. Since the PKCδIV, V, VI, and VII isoforms were expressed in a testis-specific manner, we thought that PKCδ knockout mice might have some problems in the early stages of development such as fertilization, early cleavage, and implantation. However, our results demonstrated the presence of 8–12 fetal sacs in the uterus of 10 out of 11 mother mice. The genotype of the fetuses in the fetal sacs at E11.5 is shown in Table 3A. It suggests that all genotypes of WT, He, and KO follow the Mendelian rule (χ2(2) = 2.077, n.s.), and fertilization, early cleavage, and implantation (placenta confirmed) were not problematic. However, as shown in Table 3B, the survival rate of KO fetuses was significantly lower than that of the WT and He embryos at E11.5 (χ2(2) = 30.892, p <0.001). This suggests that KO fetuses have problems developing in the mother’s body, which explains the one possible reason for the low birth rate of KO mice. The implantation rate of PKCδ KO fetuses was 23.1% of the total, but the survival rate decreased in the mother’s body and further decreased to 3.4% at 4 weeks of age (Table 1).

Table 3. Number of fetal sacs and embryos at E11.5.

(A)
Number of fetal sacs holding fetuses of each indicated genotype at E11.5
WT He KO
Total 22 58 24*
Pregnancy Rate 21.2% (n = 22/104) 55.8% (n = 58/104) 23.1% (n = 24/104)
* One case was absorbed.
χ2(2) = 2.077, n.s.
(B)
Number of fetuses of each indicated genotype at E11.5
WT He KO
Alive 16 52 7
Dead 6 6 17
Surviving rate of fetus 72.7% (n = 16/22) 89.7% (n = 52/58) 29.2% (n = 7/24)
χ2(2) = 30.892, p < 0.001

After mating of PKCδ He mice, 11.5-day-old embryos from mothers (n = 11) were analyzed. (A) Genetic analysis of fetal sac was carried out. A Chi-squared test was applied to test whether the rate of pregnancy follows Mendelian rules. (B) The embryos with confirmed heartbeat were denoted as surviving embryos. Difference in the rate of survival among the genotypes was tested using a Chi-squared test.

Genotypes: WT, wild type mice; He, heterozygous knockout mice; KO, homozygous PKCδ-/- mice (PKCδ knockout).

As representative E11.5 samples, fetuses of mother numbers 8 and 11 are shown in Fig 6A and 6B. Fetuses with heartbeats on E11.5 (fetus numbers 2 (WT) and 7 (KO) in Fig 6A, and 3 (WT) and 10 (KO) in Fig 6B) were fixed using 4% paraformaldehyde solution and stained with HE for histological examination (Fig 7A and 7B). The fetuses of PKCδ KO mice were slightly smaller than those of WT mice, and their Sclerotome and spinal cord appeared to be immature compared with those of the WT mice (Figs 6 and 7). Although there was no difference in the size of the heart between KO and WT mice, the ventricular wall was thin in the KO mice. These are especially mesoderm-derived organs. Additionally, there were no obvious differences between the PKCδ He and PKCδ WT fetuses. These findings suggest that at E11.5, PKCδ KO mice have an overall poor developmental status, and their cause of death is considered to be poor overall growth rather than organ-specific abnormalities. These results indicate that the absence of the PKCδ gene is detrimental to fetal growth.

Fig 6. 11.5-day-old embryo (E11.5) generated by crossing He × He.

Fig 6

The embryos of two mice out of 11 mother mice in Table 2 are shown in (A) and (B). The photographs show each individual and genotypes determined by their amniotic membranes. In (A), fetus number 4 was already absorbed. Scale bars represent 2 mm.

Fig 7. Histological analysis of WT and KO mice on E11.5.

Fig 7

(A) Hematoxylin and eosin-stained image obtained by vertically cutting embryo numbers 2 (WT) and 7 (KO) in Fig 5A. (B) Hematoxylin and eosin-stained image obtained by vertically cutting embryos 3 (WT) and 10 (KO) in Fig 5B. Scale bars represent 1 mm. a, spinal cord; b, sclerotome.

Discussion

In the present study, we designed a murine model lacking exon 7 of Prckd, which is utilized by most of the reported PKCδ splicing variants when generating PKCδ conditional knockouts. Therefore, LoxP sequences were inserted in the 5ʹ upstream and 3ʹ downstream regions of exon 7 of the Prckd gene encoding PKCδ, to generate PKCδ-flox mice using the C57BL/6N-derived RENKA ES cell line. By mating these mice with Cre mice according to each research objective, it is possible to produce mice with a conditional knockout of PKCδ molecules. Other studies on PKCδ knockout mice have been reported; however, they only knocked out PKCδI and δII, and did not achieve a complete knockout of all PKCδ family of proteins [17,18]. For instance, considering that the first exon of the PKCδ gene is a non-coding exon [28], Leitges M et al. generated PKCδ KO mice by eliminating the function of the second exon of the PKCδ gene. The resulting mice had a 129/SV background, developed normally, and were fertile. Moreover, these PKCδ KO mice had markedly increased arteriosclerotic lesions in the vein grafts compared with WT mice. Those mice with atherosclerotic lesions also had substantially more smooth muscle cells than the WT animals [17]. Additionally, Miyamoto et al. generated PKCδ knockout mice lacking exons 2 and 3. These mice had a 129/Sv background, were fertile, and survived up to 12 months despite the excessive proliferation of B cells and autoimmunity that was observed due to the lack of PKCδ [18]. Furthermore, in 2002, Mecklenbrauker et al. reported that PKCδ is an essential component of signaling pathways specific for inducing tolerance in B cells [19].

Considering these other related studies, ours is the first to generate PKCδ KO mice with a C57BL/6N background that can reliably delete the six PKCδ species (PKCδI, II, IV, V, VI, and VII). Many reports have described the importance of PKCδ functions, including its role in cell proliferation, cell death, and as a tumor suppressor [911,3234]. In addition, the PKCδ gene produces several molecules from a single gene [2024]. These findings suggest that a single mutation deletes more than one PKCδ molecular species, indicating the importance of this mouse model. Moreover, murine PKCδ contains a recognition sequence (DILD) for caspase-3, a member of the caspase family of cysteine proteases in its V3 domain, indicating its involvement in apoptosis [16,3436].

Previous studies using PKCδI- and δII-null mice have investigated its role in apoptosis [37,38], defective osteoblast differentiation during embryonic development [39], defective osteoclastic bone resorption [40], as well as an increased proliferation of, and autoimmunity toward, B cells [11,18]. Sites summarizing studies on PKCδ KO mice can be found online (http://www.informatics.jax.org/marker/phenotypes/MGI:97598).

In the present study, whole-body PKCδ deficiency resulted in the survival of only 3.4% offspring, which differs significantly from previous studies, which reported no apparent issues in PKCδ KO fertility. The discrepancy in these findings may be attributed to differences in the missing PKCδ molecular species due to either differences in the gene knockout position or the mouse strain. Here we have generated a mouse that lacks exon 7. This may have resulted in the expression of a new PKCδ molecular species, resulting in a phenotypic difference from previous PKCδ KO mice. Moreover, considering that PKCδ effectively utilizes the PKCδ gene, it may be possible to discover that another splicing variant is expressed, which functions in the biological reactions of mice having exon deficiency.

It also has been reported that the experiments with sperm from PKCδ KO male mice and oocytes from WT female mice resulted in lower fertilization rates and lower early cleavage rates [41]. However, in our study, results of in vitro fertilization with eggs from three WT females using one male PKCδ KO mouse spermatozoa showed no differences from WT male spermatozoa when comparing fertilization rates and developmental conditions up to two cells. Together with the results of several genotypic mating combinations (Table 2), the reproductive performance of PKCδ KO males did not appear to be affected. However, due to the small number of cases, further research is expected on the reproductive ability of PKCδ KO mice.

Examination of the number of implantations due to the mating of PKCδ He showed that the numbers of WT, He, and KO fetuses were almost consistent with Mendelian law, and the implantation of PKCδ KO fertilized eggs was not low. The main reason for the birth of only 3.4% PKCδ KO mice, may be due to the developmental failure of the fetuses as observed by the analysis of E11.5, generated by mating PKCδ He. However, PKCδ KO did not result in complete embryonic lethality. Future studies are required to determine the reason for the low PKCδ KO birth rate, including the potential use of other PKC molecules to successfully complement its function. Moreover, this low birth rate in mice may also suggest that similar issues will arise in human fetuses with PKCδ KO, given the small number of pregnancies.

PKCδ may be associated with fetal underdevelopment during pregnancy. A possible difference in the present study from previous reports on PKCδ KO mice may be the neglect of the presence of PKCδIV, V, VI, and VII produced by alternative splicing. PKCδ IV, V, VI, and VII are expressed in adult mice in a testis-specific manner and have not been studied in fetal development [21]. PKCδIV and V, and PKCδVI and VII are paired with normal and disrupted caspase-3 recognition sequences. These molecules are also deficient in the KO mice in this study. The mice generated in the present study will also be useful for further studies on PKCδIV, V, VI, and VII species.

Notably, of the nine KO mice that exhibited spontaneous death, born from crosses between PKCδ He mice, seven died within the first year of life, while all PKCδ KO mice had a short lifespan. Analysis of three 24-week-old PKCδ KO mice and one 16-week-old PKCδ KO mouse showed enlarged hearts in three animals, with two exhibiting calcification in the left ventricle or mitral valves. Moreover, staining of these heart tissues revealed an increase in elastic fibers in the endocardium, which may have led to the calcification within the heart. In addition, inflammation was observed in the lungs of three of the four PKCδ KO mice; however, an increase in fiber was not obvious. Although no calcifications were observed in the hearts of two cases, one had an enlarged heart. It was suspected that inflammation in the lungs might have resulted from a decrease in cardiac function. This is the first study to report calcification in the heart and inflammation in the lungs of PKCδ KO mice. Moreover, as many of the PKCδ KO mice died while they were still fetuses, resulting in small litter sizes, the analysis of adult animals is not considered to be sufficient. In the future, the function of PKCδ in heart and lung lesions, as well as other organs, should be investigated in a larger population.

It has been previously reported that PKCδ is expressed in the mouse heart [42]. Recently, PKCδ and PKCε double knockout mice demonstrated cardiac hypertrophy and thickening of the ventricular wall of the fetal heart [43]. However, in the present study, we observed that some mice had cardiac enlargement and calcification due to a deficiency present only in the PKCδ gene. This enlargement of the heart in PKCδ KO mice may correspond with the hypertrophy reported previously by Song et al. [43]. However, further detailed analysis is required to unambiguously ascertain the cause of the observed enlargement.

It has also been reported that PKCδ gene-deficient mice have altered immune function. PKCδ KO mice develop autoimmune diseases with aging, indicating that PKCδ plays a role in B cell tolerance of autoantigen induction [19]. Research on human lesions has advanced as well. For instance, a missense mutation (c.1528G>A) in the human PKCδ gene via a single nucleotide substitution replaces the amino acid glycine with serine (p. G510S) in children born to parents heterozygous for this missense mutation of PKCδ gene. Children homozygous for this mutation are reported to have systemic lupus erythematosus, caused by a marked decrease in PKCδ function [44]. Furthermore, patients with a homozygous missense mutation (c.1840C>T) in the human PKCδ gene, involving the substitution (p. R614W) from arginine to tryptophan, have several autoantibodies, systemic lymphadenopathy, and hepatosplenomegaly [45]. Since single mutations can cause severe symptoms, gene products must be comprehensively analyzed, particularly for genes like PKCδ, which encode multiple proteins by alternative splicing. Therefore, the mice produced in the current study have the potential to elucidate the effects of the multiple protein variants in mice, as well as humans.

PKCδ also plays a role in inflammatory diseases such as sepsis [46,47], and is reportedly associated with diabetes, with PKCδ regulating glucose production in rats [48], and increased PKCδ expression and activation in diabetic rats [49]. Moreover, continuous hyperglycemia is a common event in patients with type I and type II diabetes. It is reported that PKCδ is involved in advanced glycation end product-induced apoptosis produced by this hyperglycemic exposure [50,51]. Hence, it is expected that the mice produced in the present study will contribute to the elucidation of important functions of PKCδ and its role in various diseases.

Supporting information

S1 Raw images. Original gel images of Fig 2B-1 (DIG), Fig 2B-2 (EtBr) and Fig 2C.

(PDF)

Acknowledgments

We thank the Media Technology Laboratory of Tokyo Metropolitan Institute of Medical Science for photographs and figures of mice and their tissues. We would like to thank Dr. T. Nakamachi and Dr. J. Watanabe for their cooperation in producing and maintaining PKCδ KO mice.

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

This work was supported by the JSPS KAKENHI Grant-in-Aid for Scientific Research (C) grant numbers 21590204:YSN and 15K10689:YSN, and JSPS KAKENHI Grant Number JP 16H06276 (AdAMS):HK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Inoue M, Kihsimoto A, Takai Y, Nishizuka Y. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum. J Biol Chem. 1977;252(21): 7603–7609. [PubMed] [Google Scholar]
  • 2.Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992;258(5082): 607–614. doi: 10.1126/science.1411571 [DOI] [PubMed] [Google Scholar]
  • 3.Steinberg SF. Structural basis of protein kinase c isoform function. Physiol Rev. 2008;88(4): 1341–1378. doi: 10.1152/physrev.00034.2007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kikkawa U, Matsuzaki H, Yamamoto T. Protein kinase C delta (PKC delta): activation mechanisms and functions. J Biochem. 2002;132(6): 831–839. doi: 10.1093/oxfordjournals.jbchem.a003294 [DOI] [PubMed] [Google Scholar]
  • 5.Basu A, Pal D. Two faces of protein kinase Cδ: the contrasting roles of PKCδ in cell survival and cell death. ScientificWorldJournal. 2010;10: 2272–2284. doi: 10.1100/tsw.2010.214 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Salzer E, Santos-Valente E, Keller B, Warnatz K, Boztug K. Protein Kinase C δ: A gatekeeper of immune homeostasis. J Clin Immunol. 2016;36(7): 631–640. doi: 10.1007/s10875-016-0323-0 Epub 2016 Aug 19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Watanabe T, Ono Y, Taniyama Y, Hazama K, Igarashi K, Ogita K, et al. Cell division arrest induced by phorbol ester in CHO cells overexpressing protein kinase C-δ subspecies. Proc Natl Acad Sci U S A. 1992;89: 10159–10163. doi: 10.1073/pnas.89.21.10159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Emoto Y, Manome Y, Meinhardt G, Kisaki H, Kharbanda S, Robertson M, et al. Proteolytic activation of protein kinase C δ by an ICE-like protease in apoptotic cells. EMBO J. 1995;14: 6148–6156. doi: 10.1002/j.1460-2075.1995.tb00305.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ghayur BT, Hugunin M, Talanian R V, Ratnofsky S, Quinlan C, Emoto Y, et al. Proteolytic activation of protein kinase c δ by an ice/ced 3-like protease induces characteristics of apoptosis. J Exp Med. 1996;184;6: 2399–2404. doi: 10.1084/jem.184.6.2399 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Perletti GP, Marras E, Concari P, Piccinini F, Tashjian AH Jr. PKCδ acts as a growth and tumor suppressor in rat colonic epithelial cells. Oncogene. 1999;18: 1251–1256. doi: 10.1038/sj.onc.1202408 [DOI] [PubMed] [Google Scholar]
  • 11.Jackson D, Zheng Y, Lyo D, Shen Y, Nakayama K, Nakayama KI, et al. Suppression of cell migration by protein kinase Cδ. Oncogene. 2005;24: 3067–3072. doi: 10.1038/sj.onc.1208465 [DOI] [PubMed] [Google Scholar]
  • 12.Zhang LL, Cao FF, Wang Y, Meng FL, Zhang Y, Zhong DS, et al. The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials. Clin Transl Oncol. 2015;17: 371–377. doi: 10.1007/s12094-014-1241-3 [DOI] [PubMed] [Google Scholar]
  • 13.Newton AC. Protein Kinase C as a tumor suppressor. Semin Cancer Biol. 2018;48: 18–26. doi: 10.1016/j.semcancer.2017.04.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Denning MF, Wang Y, Nickoloff BJ, Wrone-Smith T. Protein kinase Cσ is activated by caspase-dependent proteolysis during ultraviolet radiation-induced apoptosis of human keratinocytes. J Biol Chem. 1998;273: 29995–30002. doi: 10.1074/jbc.273.45.29995 [DOI] [PubMed] [Google Scholar]
  • 15.Li L, Lorenzo PS, Bogi K, Blumberg PM, Yuspa SH. Protein kinase Cδ targets mitochondria, alters mitochondrial membrane potential, and induces apoptosis in normal and neoplastic keratinocytes when overexpressed by an adenoviral vector. Mol Cell Biol. 1999;19: 8547–8558. doi: 10.1128/MCB.19.12.8547 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Reyland ME, Barzen KA, Anderson SM, Quissell DO, Matassa AA. Activation of PKC is sufficient to induce an apoptotic program in salivary gland acinar cells. Cell Death Differ. 2000;7: 1200–1209. doi: 10.1038/sj.cdd.4400744 [DOI] [PubMed] [Google Scholar]
  • 17.Leitges M, Mayr M, Braun U, Mayr U, Li C, Pfister G, et al. Exacerbated vein graft arteriosclerosis in protein kinase Cδ-null mice. J Clin Invest. 2001;108: 1505–1512. doi: 10.1172/JCI12902 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Miyamoto A, Nakayama K, Imaki H, Hirose S, Jiang Y, Abe M, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ. Nature. 2002;416: 865–869. doi: 10.1038/416865a [DOI] [PubMed] [Google Scholar]
  • 19.Mecklenbräuker I, Saijo K, Zheng NY, Leitges M, Tarakhovsky A. Protein kinase Cdelta controls self-antigen-induced B-cell tolerance. Nature. 2002;416(6883): 860–865. doi: 10.1038/416860a [DOI] [PubMed] [Google Scholar]
  • 20.Sakurai Y, Onishi Y, Tanimoto Y, Kizaki H. Novel protein kinase C δ isoform insensitive to caspase-3. Biol Pharm Bull. 2001;24: 973–977. doi: 10.1248/bpb.24.973 [DOI] [PubMed] [Google Scholar]
  • 21.Kawaguchi T, Niino Y, Ohtaki H, Kikuyama S, Shioda S. New PKCδ family members, PKCδIV, δV, δVI, and δVII are specifically expressed in mouse testis. FEBS Lett. 2006;580: 2458–2464. doi: 10.1016/j.febslet.2006.03.084 [DOI] [PubMed] [Google Scholar]
  • 22.Kim JD, Seo KW, Lee EA, Quang NN, Cho HR, Kwon B. A novel mouse PKCδ splice variant, PKCδIX, inhibits etoposide-induced apoptosis. Biochem Biophys Res Commun. 2011;410: 177–182. doi: 10.1016/j.bbrc.2011.04.096 [DOI] [PubMed] [Google Scholar]
  • 23.Ueyama T, Ren Y, Ohmori S, Sakai K, Tamaki N, Saito N. cDNA cloning of an alternative splicing variant of protein kinase C δ (PKC δIII), a new truncated form of PKCδ, in rats. Biochem Biophys Res Commun. 2000;269: 557–563. doi: 10.1006/bbrc.2000.2331 [DOI] [PubMed] [Google Scholar]
  • 24.Apostolatos H, Apostolatos A, Vickers T, Watson JE, Song S, Vale F, et al. Vitamin A metabolite, all-trans-retinoic acid, mediates alternative splicing of protein kinase C δVIII (PKCδVIII) isoform via splicing factor SC35. J Biol Chem. 2010;285: 25987–25995. doi: 10.1074/jbc.M110.100735 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Patel NA, Song SS, Cooper DR. PKCδ alternatively spliced isoforms modulate cellular apoptosis in retinoic acid-induced differentiation of human NT2 cells and mouse embryonic stem cells. Gene Expr. 2005;13: 73–84. doi: 10.3727/000000006783991890 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Jiang K, Apostolatos AH, Ghansah T, Watson JE, Vickers T, Cooper DR, et al. Identification of a novel antiapoptotic human protein kinase C delta isoform, PKCdeltaVIII in NT2 cells. Biochemistry. 2008;47: 787–797. doi: 10.1021/bi7019782 Epub 2007 Dec 20. [DOI] [PubMed] [Google Scholar]
  • 27.Apostolatos A, Song S, Acosta S, Peart M, Watson JE, Bickford P, et al. Insulin promotes neuronal survival via the alternatively spliced protein kinase CδII isoform. J Biol Chem. 2012;287: 9299–9310. doi: 10.1074/jbc.M111.313080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Kwang S Suh, Tatunchaka TT, Crutchley JM, Edwards LE, Mari KG, Yuspa SH. Genomic structure and promoter analysis of PKC-delta. Genomics. 2003;82; 57–67. doi: 10.1016/s0888-7543(03)00072-7 [DOI] [PubMed] [Google Scholar]
  • 29.Mishina M, Sakimura K. Conditional gene targeting on the pure C57BL/6 genetic background. Neurosci Res. 2007;58: 105–112. doi: 10.1016/j.neures.2007.01.004 [DOI] [PubMed] [Google Scholar]
  • 30.Kido T, Arata S, Suzuki R, Hosono T, Nakanishi Y, Miyazaki JI, et al. The testicular fatty acid binding protein PERF15 regulates the fate of germ cells in PERF15 transgenic mice. Dev Growth Differ. 2005;47: 15–24. doi: 10.1111/j.1440-169x.2004.00775.x [DOI] [PubMed] [Google Scholar]
  • 31.Yuan R, Tsaih SW, Petkova SB, Marin de Evsikova C, Xing S, Marion MA, et al. Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell. 2009;8(3): 277–287. doi: 10.1111/j.1474-9726.2009.00478.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Yoshida K. PKCδ signaling: Mechanisms of DNA damage response and apoptosis. Cell Signal. 2007;19: 892–901. doi: 10.1016/j.cellsig.2007.01.027 [DOI] [PubMed] [Google Scholar]
  • 33.Breitkreutz D, Braiman-Wiksman L, Daum N, Denning MF, Tennenbaum T. Protein kinase C family: On the crossroads of cell signaling in skin and tumor epithelium. J Cancer Res Clin Oncol. 2007;133: 793–808. doi: 10.1007/s00432-007-0280-3 Epub 2007 Jul 28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Dashzeveg N, Yoshida K. Crosstalk between tumor suppressors p53 and PKCδ: Execution of the intrinsic apoptotic pathways. Cancer Lett. 2016;377: 158–163. doi: 10.1016/j.canlet.2016.04.032 [DOI] [PubMed] [Google Scholar]
  • 35.DeVries TA, Neville MC, Reyland ME. Nuclear import of PKCδ is required for apoptosis: Identification of a novel nuclear import sequence. EMBO J. 2002;21: 6050–6060. doi: 10.1093/emboj/cdf606 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Baek JH, Yun HS, Kwon GT, Lee J, Kim JY, Jo Y, et al. PLOD3 suppression exerts an anti-tumor effect on human lung cancer cells by modulating the PKC-delta signaling pathway. Cell Death Dis. 2019;10(3): 1–13. doi: 10.1038/s41419-019-1405-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Humphries MJ, Limesand KH, Schneider JC, Nakayama KI, Anderson SM, Reyland ME. Suppression of apoptosis in the protein kinase Cδ null mouse in vivo. J Biol Chem. 2006;281: 9728–9737. doi: 10.1074/jbc.M507851200 [DOI] [PubMed] [Google Scholar]
  • 38.Katie G, Duong H, Newton J, Rounds S, Choudhary G, Harrington EO. Heterogeneity in apoptotic responses of microvascular endothelial cells to oxidative stress. J Cell Physiol. 2012;227: 1899–1910. doi: 10.1002/jcp.22918 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Tu X, Joeng KS, Nakayama KI, Nakayama K, Carroll TJ, Mcmahon AP, et al. Noncanonical Wnt signaling through G protein-linked PKCδ activation promotes bone formation. Dev Cell. 2007;12: 113–127. doi: 10.1016/j.devcel.2006.11.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Khor EC, Abel T, Tickner J, Chim SM, Wang C, Cheng T, et al. Loss of protein kinase C-δ protects against lps-induced osteolysis owing to an intrinsic defect in osteoclastic bone resorption. PLoS One. 2013;8. doi: 10.1371/journal.pone.0070815 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ma W, Baumann C, Viveiros MM. Lack of protein kinase C-delta (PKCδ) disrupts fertilization and embryonic development. Mol Reprod Dev. 2015;82: 797–808. doi: 10.1002/mrd.22528 Epub 2015 Aug 14. [DOI] [PubMed] [Google Scholar]
  • 42.Schreiber KL, Paquet L, Allen BG, Rindt HRG. Protein kinase C isoform expression and activity in the mouse heart. Am J Physiol—Hear Circ Physiol. 2001;281: 2062–2071. doi: 10.1152/ajpheart.2001.281.5.H2062 [DOI] [PubMed] [Google Scholar]
  • 43.Song M, Matkovich SJ, Zhang Y, Hammer DJ, Dorn GW. Combined cardiomyocyte PKCδ and PKCε gene deletion uncovers their central role in restraining developmental and reactive heart growth. Sci Signal. 2015;8. doi: 10.1126/scisignal.aaa1855 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Belot A, Kasher P, Trotter E, Foray A, Debaud A, Rice G, et al. protein kinase cδ deficiency causes mendelian sle with b cell-defective apoptosis and hyperproliferation. Arthritis Rheum. 2013;65: 2161–2171. doi: 10.1002/art.38008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Kuehn HS, Niemela JE, Rangel-Santos A, Zhang M, Pittaluga S, Stoddard JL, et al. Loss-of-function of the protein kinase C δ (PKCδ) causes a B-cell lymphoproliferative syndrome in humans. Blood. 2013;121: 3117–25. doi: 10.1182/blood-2012-12-469544 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Tang Y, Soroush F, Sun S, Liverani E, Langston JC, Yang Q, et al. Protein kinase C-delta inhibition protects blood-brain barrier from sepsis-induced vascular damage. J Neuroinflammation. 2018;15: 1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Yang Q, Langston JC, Tang Y, Kiani MF, Kilpatrick LE. The role of tyrosine phosphorylation of protein kinase C delta in infection and inflammation. Int J Mol Sci. 2019;20: 1–17. doi: 10.3390/ijms20061498 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Kokorovic A, Cheung GWC, Breen DM, Chari M, Lam CKL, Lam TKT. Duodenal mucosal protein kinase C-δ regulates glucose production in rats. Gastroenterology. 2011;141: 1720–1727. doi: 10.1053/j.gastro.2011.06.042 [DOI] [PubMed] [Google Scholar]
  • 49.Li Q, Park K, Xia Y, Matsumoto M, Qi W, Fu J, et al. Regulation of macrophage apoptosis and atherosclerosis by lipid induced PKCδ isoform activation. Circ Res. 2017;121: 1153–1167. doi: 10.1161/CIRCRESAHA.117.311606 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Yang YC, Tsai CY, Chen CL, Kuo CH, Hou CW, Cheng SY, et al. Pkcδ activation is involved in ROS-mediated mitochondrial dysfunction and apoptosis in cardiomyocytes exposed to advanced glycation end products (AGEs). Aging Dis. 2018;9: 647–663. doi: 10.14336/AD.2017.0924 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Hsieh DJY, Ng SC, Zeng RY, Padma VV, Huang CY, Kuo WW. Diallyl trisulfide (DATS) suppresses AGE-induced cardiomyocyte apoptosis by targeting ROS-mediated PKCδ activation. Int J Mol Sci. 2020;21. doi: 10.3390/ijms21072608 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Diego Fraidenraich

4 Jan 2021

PONE-D-20-38543

PKCδ deficiency inhibits fetal development and is associated with heart elastic fiber hyperplasia and lung inflammation in adult PKCδ knockout mice

PLOS ONE

Dear Dr. Gotoh,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Further studies and clarifications need to be provided, including better presentation of the differences and similarities found in the new KO model relative to the old KOs, and accuracy in the description of quantitative phenotypes.

Please submit your revised manuscript by March 3rd, 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Diego Fraidenraich

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors describe a new knockout of the PKCd gene where they have targeted Exon 7. Previous knockouts have targeted the first two exons and this leaves the possibility that alternative splice forms, not using these early exons, may be expressed. In contrast, Exon 7 is required for all isoform bar IX (although this could be made clearer in Figure 1). With the new KO, embryonic survival is compromised and hardly any KO mice are generated. This is potentially important as it suggests the previous conclusion that PKCd is not needed for survival or breeding may be incorrect and it perhaps also uncovers some important in vivo roles for specific isoforms. Overall, these models could be very useful in understanding PKCd function – and this is a valid and worthwhile undertaking - but in many cases, considerable further study will be required to understand mechanism. As an initial report that PKCd may be essential, the work is quite convincing. There are however a few areas which should really be strengthened or clarified to make this case more convincingly, and there are number of other areas where current analyses could be improved.

Major Point: Clarity of the approach and comparison with other PKCd KOs

1. In the original PKCd KOs it is stated “ PKCδ–/– mice developed normally and were fertile.” https://www.jci.org/articles/view/12902 and “The PKC-δ-/- mice were viable up to 12 months of age, despite detection of auto-immune disease in these animals (see below).”https://www.nature.com/articles/416865a. The authors state in the current paper (line 75: “Although these studies reported significant findings, the PKCδ KO mice used in these studies lacked only the PKCδI and δII isoforms.” This is reastsed in the conclusion.

This is completely critical to the manuscripts originality. Both initial PKCd KO mouse models indeed targeted exons early in the gene leaving the possibility that alternative splice variants may be made. However, in Mecklenbräuker et al, it is stated that “The absence of full-length or truncated PKC-δ in lymphocytes was confirmed by immunoblot analysis of cell lysates”. Likewise in Miyamoto et al it is stated that:“Neither full-length nor truncated PKC-δ protein was detected in PKC-δ-/- mouse cells by immunoblot analysis”

While it is understood that these immunoblot analyses are far from conclusive, it would be useful to have some direct evidence that these other models do indeed still generate alternatively sliced PKCd isoforms. Are there any published studies showing alternative PKCd isoform expression in these previous KOs? Could cell lines from these KOs be tested by qPCR or Western to show other mRNAs or proteins are indeed made? The previous authors could reasonably be requested to provide cell lines to test this.

2. The authors approach was to target Exon 7 using a conditional approach, which is common to many more isoforms. However, as with the original KOs, exon specific deletions can cause all manner of unexpected effects. For example, truncated products could perhaps now be produced from the early part of the PKCd gene. Discrepancies between phenotypes might easily be caused by production of PKCd fragments acting in a dominant way. Could the authors describe why they are convinced this would not be the case? Careful use of C and N-terminal directed antibodies on lysates would be a start. qPCR to look for truncated/alternative mRNAs could be another approach.

Phenotypes of the new PKCd mouse:

There is a lack of statistical analysis throughout the manuscript. Lack of stats on all ratios being a good example. Table 1, Table 2. Chi2 tests needed on all data. In many cases this will be very convincing. For many of the embryo and tissue analyses, there are convincing differences but it is reported in an anecdotal way which could benefit from more rigorous stats.

As an example, survival data looks really convincing but it needs to be better displayed and subjected to stats. Line 236: “The lifespan of all PKCδ KO mice born …” Could this data be presented graphically as a proper survival analysis? Is there enough data fro a Kaplan Meier plot with stats to be included?

Breeding pairs from surviving PKCd KOs show convincingly that the males are fertile and provide additional indication that females may have reproductive issues. The data on the females is a little less convincing. Out of four pairs of KO x Het, three generated 3 offspring which survived to at least 4-weeks, which given the lethality of their KO is pretty good. Data with KO x WT are slightly at odds with this (all off spring died). The authors state this requires further work. This could be usefully strengthened prior to publication if numbers have been improved and also, the data might be more clearly presented with a table.

Separating causation between heart and lung pathologies is very difficult. While the authors observe changes in elastic fibres, and state this is predominant, I would urge caution on attributing this directly to loss of PKCd in this organ. With the numbers observed and the strong pathologies in both heart and lungs, further analysis is needed here with greater numbers and better statistics to (i) accurately and statistically define the problems and (ii) suggest functional experiments to test causation. This will likely involve additional conditional crosses. While I do not suggest this is done for the current report, I would suggest the text makes clear that these effects could all be secondary to other problems occurring during development.

Minor:

On line 75-77 the authors state: “PKCδ plays a critical role in B cell homeostasis and tolerance, highlighting its potential role in the treatment of autoimmune diseases [18]. “

A reference is missing from here. Two papers showed the B-cell phenotypes, both published in Nature in 2002. https://www.nature.com/articles/416860a

Line 263 “…of four KO mice, indicating bad air content, as observed by HE staining (Fig 3B). What is meant by bad air content? Do the authors mean poor lung perfusion?

Reviewer #2: Niino et al have analyzed the role of PKC delta isoforms using mouse genetics and identify requirements during heart and lung development. The scientific question, addressing PKC delta isoform diversity, and the genetic approach are excellent. However the mouse phenotyping needs to be significantly improved in order to provide any mechanistic insights into PKC delta function. A number of suggestions follow.

1. In the small percentage of surviving mice, were the authors able to confirm previously shown requirements for PKC delta in B cell and smooth muscle homeostasis?

2. The main paragraph on page 15 ending with "require further experiments" should be shortened. Can a potential maternal defect be demonstrated statistically? Can the authors speculate on a potential cause?

3. Did the authors formally demonstrated that the enlarged hearts are hypertrophied? Was cardiomyocyte cross-sectional area evaluated? Were other markers of cardiac hypertrophy evaluated? The calcification needs to be documented in more detail. Is this within ventricular muscle? Please add arrowheads to this figure to indicate the salient points. Are the authors sure the structure highlighted in Figure 4 is part of the heart rather than accumulated blood cells or debris in the ventricular lumen? The elastic fiber results should be confirmed at high magnification and with other markers. Finally, did the authors examine knockout hearts without the cardiac phenotypes?

4. The authors find that most homozygous mutant embryos die at or prior to E11.5. After histological analysis at this stage the authors conclude that cell proliferation was poor and certain organs, the heart and lung, were immature. This point needs to be analyzed in more depth. On what basis do the authors make their conclusion on proliferation? What do they mean by "immature"? Are they implying an overall growth delay? Please show how this is evident for the heart shown in B-10 compared to that in B-3 for example? The authors need to qualify the defects in the hearts in more detail, scoring for example chamber development, compact layer thickness, myocardial differentiation. Given the mortality at this time point it would also seem important to analyze earlier developmental stages.

5. Please say more about the "conspicuous deformation" seen in the lungs? What do the authors mean by the term "bad air content"?

6. Can the authors use their conditional allele to look at cell/tissue type roles of PKC delta?

7. The top panels in Figure 5 can be omitted, as can the empty panel 4. Perhaps the authors could illustrate a smaller number of control and mutant embryos at higher magnification.

Minor points

8. The pictures of the heart in Fig3 would be improved if taken under buffer (PBS) to avoid reflection.

9. Data in Table 2 should be condensed.

10. Please spell out EVG and MT on first mention in the results.

Reviewer #3: In manuscript “PKCδ deficiency inhibits fetal development and is associated with heart elastic fiber

hyperplasia and lung inflammation in adult PKCδ knockout mice“ authors Niino et al., show how depletion of PKCδ (splicing variants I, II, IV, V, VI, and VII) affects fertility and development of mice. Authors demonstrate that PKCδ -/- mice are fertile but number of PKCδ-/- offspring was reduced. Furthermore, they observed defects in heart, lung, and spleen development. Presented manuscript thus points to protentional role of PKCδ in both development and in maintenance of homeostasis. Results are clearly described. I have only minor suggestions:

- Description of Fig1 should be contain the source references

- Authors analyse four PKCδ -/- mice, which show different results. It should be summarized in table and observed phenotype should be connected to sex and age of analysed mice.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jul 1;16(7):e0253912. doi: 10.1371/journal.pone.0253912.r002

Author response to Decision Letter 0


13 Mar 2021

Response to Reviewers

Reviewer #1: The authors describe a new knockout of the PKCd gene where they have targeted Exon 7. Previous knockouts have targeted the first two exons and this leaves the possibility that alternative splice forms, not using these early exons, may be expressed. In contrast, Exon 7 is required for all isoform bar IX (although this could be made clearer in Figure 1). With the new KO, embryonic survival is compromised and hardly any KO mice are generated. This is potentially important as it suggests the previous conclusion that PKCd is not needed for survival or breeding may be incorrect and it perhaps also uncovers some important in vivo roles for specific isoforms. Overall, these models could be very useful in understanding PKCd function ? and this is a valid and worthwhile undertaking - but in many cases, considerable further study will be required to understand mechanism. As an initial report that PKCd may be essential, the work is quite convincing. There are however a few areas which should really be strengthened or clarified to make this case more convincingly, and there are number of other areas where current analyses could be improved.

Response: Thank you for your helpful feedback. In an effort to investigate the function of PKCδ, we designed PKCδ floxed mice with organ-and time-specific defects. However, unlike the results presented previously by Leitges et al., (17), Miyamoto et al., (18), and Mecklenbrauker et al., (19), PKCδ deficiency had a lethal effect on our knockout mice. Although some of the quantitative analyses are incomplete, we have chosen to publish the preliminary results in PLOS ONE, as we believe that they are critical and of high importance in the field.

The phenotypes of the previously reported PKCδKO mice have now been described in the Discussion section of the manuscript (Lines 383-393, in “Revised_Manuscript_Clean”).

Please find our point-by-point responses to each of your comments below.

Major Point: Clarity of the approach and comparison with other PKCd KOs

1. In the original PKCd KOs it is stated “ PKCδ?/? mice developed normally and were fertile.” https://www.jci.org/articles/view/12902 and “The PKC-δ-/- mice were viable up to 12 months of age, despite detection of auto-immune disease in these animals (see below).”https://www.nature.com/articles/416865a. The authors state in the current paper (line 75: “Although these studies reported significant findings, the PKCδ KO mice used in these studies lacked only the PKCδI and δII isoforms.” This is reastsed in the conclusion.

This is completely critical to the manuscripts originality. Both initial PKCd KO mouse models indeed targeted exons early in the gene leaving the possibility that alternative splice variants may be made. However, in Mecklenbrauker et al, it is stated that “The absence of full-length or truncated PKC-δ in lymphocytes was confirmed by immunoblot analysis of cell lysates”. Likewise in Miyamoto et al it is stated that:“Neither full-length nor truncated PKC-δ protein was detected in PKC-δ-/- mouse cells by immunoblot analysis”

While it is understood that these immunoblot analyses are far from conclusive, it would be useful to have some direct evidence that these other models do indeed still generate alternatively sliced PKCd isoforms. Are there any published studies showing alternative PKCd isoform expression in these previous KOs? Could cell lines from these KOs be tested by qPCR or Western to show other mRNAs or proteins are indeed made? The previous authors could reasonably be requested to provide cell lines to test this.

Response: Due to the molecular structure of the mouse PKCδ, the N-terminal antibody recognizes PKCδI, δII, and δIX; but, cannot respond to δIV, δV, δVI, and δVII. Meanwhile, the C-terminal antibody cannot recognize PKCδVI and δVII. Analysis in adult mice also revealed that PKCδIV, δV, δVI, and δVII are tissue specific. Previously, Leitges, M et al generated PKCδ KO mice, and used Santa Cruz antibodies for western blotting; however, the epitope of that antibody was not mentioned (17, J. Clin. Invest. 108:1505-1512 (2001)). Meanwhile, Mecklenbrauker, I. et al used cell lysates of PKCδ KO mice produced by Leitges, M et al to perform western blotting with anti-PKCδ antibody (BD Transduction Laboratory) and found that no full-length or truncated PKCδ was present in the lymphocytes of PKCδ null mice (19, Nature, 416, 860-865, 2002). Miyamoto et al also performed western blotting using monoclonal antibodies to mouse PKCδ (BD Transduction Laboratories) using lysates of each organ of WT mice; however, splicing variants (PKCδIV, δV, δVI, δVII, which are abundantly expressed in the testis) could not be confirmed (18, Nature, 416, 865-869, 2002). Moreover, the data in these papers consists of short cropped gel lanes, making it unclear if PKCδ species with different molecular weights were detected. If molecules of varying molecular weights are not known, it is possible that a new band may be regarded as a non-specific band or artifact due to the nature of western blotting. Since the PKCδ gene produces several molecular species, there is no antibody that can recognize all molecular species, and it is difficult to find a good antibody that can be detected by western blotting.

Moreover, we have not observed previous studies that detected PKCδ molecules with small molecular weights in KO mice. Further, unfortunately, the main investigator, YSN, has withdrawn from the study making it impossible to perform western blotting and qPCR with these KO mice.

2. The authors approach was to target Exon 7 using a conditional approach, which is common to many more isoforms. However, as with the original KOs, exon specific deletions can cause all manner of unexpected effects. For example, truncated products could perhaps now be produced from the early part of the PKCd gene. Discrepancies between phenotypes might easily be caused by production of PKCd fragments acting in a dominant way. Could the authors describe why they are convinced this would not be the case? Careful use of C and N-terminal directed antibodies on lysates would be a start. qPCR to look for truncated/alternative mRNAs could be another approach.

Response: Thank you for your comments. We designed our model to lack the exons utilized by most of the reported splice variants when creating PKCδ conditional knockout mice. As Reviewer#1 pointed out, previously reported PKCδ KO lacks exon 2 or 3 of the PKCδ gene (28, Suh KS et al. Genomics 2003, 82 57-67), with other splice variants potentially expressed. However, it was not possible to compare our mice with those previously reported. Additionally, studies on splice variants are limited and prevent us from adequately addressing the reviewer's question. We have, therefore, included this point in the revised Discussion as we are unable to fully rule out the possibility that the truncated fragment acts as a dominant negative in our KO mice (Lines 412-416, in “Revised_Manuscript_clean”).

Phenotypes of the new PKCd mouse:

There is a lack of statistical analysis throughout the manuscript. Lack of stats on all ratios being a good example. Table 1, Table 2. Chi2 tests needed on all data. In many cases this will be very convincing. For many of the embryo and tissue analyses, there are convincing differences but it is reported in an anecdotal way which could benefit from more rigorous stats.

Response: Since the number of tables has increased, the numbers have changed.

Tables 1 and 4 were subjected to statistical analysis. In Table 1, the phenotypes of pups born by mating PKCδ He mice were statistically analyzed against Mendel's laws. In Table 4, the phenotype of 11.5-day-old embryos of mother mice (n = 11) pregnant by mating PKCδ He mice was statistically analyzed against Mendel's laws. The content described in the text are summarized in Tables 2 and 3.

As an example, survival data looks really convincing but it needs to be better displayed and subjected to stats. Line 236: “The lifespan of all PKCδ KO mice born …” Could this data be presented graphically as a proper survival analysis? Is there enough data fro a Kaplan Meier plot with stats to be included?

Response: Kaplan Meier plot with stats survivorship curves for the nine PKCδ KO mice described here by the reviewer were generated and presented in Fig.3.

Breeding pairs from surviving PKCd KOs show convincingly that the males are fertile and provide additional indication that females may have reproductive issues. The data on the females is a little less convincing. Out of four pairs of KO x Het, three generated 3 offspring which survived to at least 4-weeks, which given the lethality of their KO is pretty good. Data with KO x WT are slightly at odds with this (all off spring died). The authors state this requires further work. This could be usefully strengthened prior to publication if numbers have been improved and also, the data might be more clearly presented with a table.

Response: This data was presented in Table 2.

It was not possible to perform multiple crosses between PKCδ KO mice and other genotypes due to the small number of KO mice and their short life span. Hence, the small number of experiments makes it difficult to obtain definitive results on parental fertility. In fact, a very large number of rearings was required to obtain data on pregnancy and birth in PKCδ KO mice, which we could not sufficiently perform. In addition, the main researcher, YSN, has retired from research, making it impossible for us to perform additional animal studies. Although PKCδ KO females may have issues completing pregnancy and delivering their pups, while the pups born from PKCδ KO females may also have problems with growth, we are unable to adequately demonstrate this due to the small numbers. We have, therefore, added in the Discussion that further experiments are needed on a larger population of mice. We believe that research on the reproductive function of PKCδ is the next step.

Separating causation between heart and lung pathologies is very difficult. While the authors observe changes in elastic fibres, and state this is predominant, I would urge caution on attributing this directly to loss of PKCd in this organ. With the numbers observed and the strong pathologies in both heart and lungs, further analysis is needed here with greater numbers and better statistics to (i) accurately and statistically define the problems and (ii) suggest functional experiments to test causation. This will likely involve additional conditional crosses. While I do not suggest this is done for the current report, I would suggest the text makes clear that these effects could all be secondary to other problems occurring during development.

Response: We believe that additional studies with a larger population size that will allow for more detailed statistical analyses, are required to assess the lesions observed in the tissues of adult PKCδ KO mice, as Reviewer #1 indicated. This has been included in the Discussion section of the revised manuscript.

Minor:

On line 75-77 the authors state: “PKCδ plays a critical role in B cell homeostasis and tolerance, highlighting its potential role in the treatment of autoimmune diseases [18]. “

A reference is missing from here. Two papers showed the B-cell phenotypes, both published in Nature in 2002. https://www.nature.com/articles/416860a

Response: We apologize for this oversight. The study published by Dr. Mecklenbrauker, I. et al. has now been included in the manuscript (Line 79 in “Revised_Manuscript_clean”).

Line 263 “…of four KO mice, indicating bad air content, as observed by HE staining (Fig 3B). What is meant by bad air content? Do the authors mean poor lung perfusion?

Response: As shown in Fig. 3B and Fig. 4B, it was histologically confirmed that there is an area with an poorly air space in the lungs of KO mice compared to WT.

Reviewer #2: Niino et al have analyzed the role of PKC delta isoforms using mouse genetics and identify requirements during heart and lung development. The scientific question, addressing PKC delta isoform diversity, and the genetic approach are excellent. However the mouse phenotyping needs to be significantly improved in order to provide any mechanistic insights into PKC delta function. A number of suggestions follow.

Response: Thank you very much for your careful review of our manuscript and for your helpful feedback.

In an effort to investigate the function of PKCδ, we designed PKCδ floxed mice with organ-and time-specific defects. However, unlike the results presented previously by Leitges et al., (17), Miyamoto et al., (18), and Mecklenbrauker et al., (19), PKCδ deficiency had a lethal effect on our knockout mice. Although some of the quantitative analyses are incomplete, we have chosen to publish the preliminary results in PLOS ONE, as we believe they are of high importance and critical to the field.

The phenotypes of the previously reported PKCδ KO mice, as well as those of the PKCδ KO mice generated in the current study, are described in the revised Discussion.

Below we have addressed each of your comment in a point-by-point manner. Please note that the numbers in the figures and tables have changed.

1.In the small percentage of surviving mice, were the authors able to confirm previously shown requirements for PKC delta in B cell and smooth muscle homeostasis?

Response: The effect of PKCδ in B-cell and smooth muscle homeostasis, previously reported in studies of PKCδ KO mice, has not been confirmed by our research.

2.The main paragraph on page 15 ending with "require further experiments" should be shortened.

Response: Thank you for your suggestion. Accordingly, we have summarized the content and shortened the paragraph.

Can a potential maternal defect be demonstrated statistically?

Response: Unfortunately, due to the small number of KO mice and their short life span, statistical analysis of a potential PKCδ KO maternal defect could not be shown.

Can the authors speculate on a potential cause?

Response: To date, the only analysis related to female-specific organs, including the ovaries, fallopian tube, or uterus of mice with PKCδ4-7, was an RT-PCR study performed by Kawaguchi et al on uterine tissue (20). It is, therefore, entirely speculative that PKCδ KO mouse eggs may exhibit defects in implantation through to early development in utero. Alternatively, the uterus of PKCδ KO mice may exhibit challenges with placental function or may not respond well to early fetal development in utero.

3. Did the authors formally demonstrated that the enlarged hearts are hypertrophied?

Response: Fig. 4A shows the organs of WT and KO litter mice. Size markers have been provided.

Was cardiomyocyte cross-sectional area evaluated?

Response: No, cardiomyocyte cross-sectional area has not been assessed as it was difficult to align the faces of the sections, and it was not possible to analyze the cross-sectional area of tissues and cells.

Were other markers of cardiac hypertrophy evaluated?

Response: Unfortunately, we have not analyzed cardiac hypertrophy.

The calcification needs to be documented in more detail. Is this within ventricular muscle?

Response: Photographs of the heart used for tissue analysis were presented in Fig 4C.

The calcified mass was not in the myocardium but in the subendocardium.

Please add arrowheads to this figure to indicate the salient points.

Response: The arrows were added to Fig 4 and Fig 5 to show the calcified mass in the heart.

Are the authors sure the structure highlighted in Figure 4 is part of the heart rather than accumulated blood cells or debris in the ventricular lumen?

Response: The structures indicated by the arrows in Fig 4B and Fig 5 are white calcified masses in Fig 4C, not blood cells or debris accumulated in the ventricular lumen.

The elastic fiber results should be confirmed at high magnification and with other markers.

Response: We agree that identification of elastic fibers is more relevant that other markers. However, the main researcher (YSN) has retired preventing us from performing additional studies including the staining of additional markers.

Finally, did the authors examine knockout hearts without the cardiac phenotypes?

Response: Yes, we examined the hearts of knockout mice without the cardiac phenotype. No differences from WT were observed in the hearts of knockout mice without cardiac phenotype. This has been included in the revised manuscript (Lines 291-293, in “Revised_Manuscript_clean”).

4. The authors find that most homozygous mutant embryos die at or prior to E11.5. After histological analysis at this stage the authors conclude that cell proliferation was poor and certain organs, the heart and lung, were immature. This point needs to be analyzed in more depth. On what basis do the authors make their conclusion on proliferation? What do they mean by "immature"?

Response: Reviewer # 2 is correct. Regarding the tissue section, we thought that the cell density of the KO tissue was coarse and that the structure was simple. However, we deleted our argument on this because they lacked scientific evidence such as measurement. We are unable to perform additional analyses. Therefore, the explanation has been revised, including the deletion of the description so that the result can be confirmed only by visual inspection.

Are they implying an overall growth delay? Please show how this is evident for the heart shown in B-10 compared to that in B-3 for example? The authors need to qualify the defects in the hearts in more detail, scoring for example chamber development, compact layer thickness, myocardial differentiation.

Response: We agree that more in-depth analysis regarding the development of the KO heart is required. Therefore, we deleted the description of the 11.5-day embryonic heart.

Given the mortality at this time point it would also seem important to analyze earlier developmental stages.

Response: To understand the function of PKCδ in embryogenesis, we agree that it is necessary to analyze the fetal stage earlier than E11.5. We hope to address this in a future study.

5. Please say more about the "conspicuous deformation" seen in the lungs?

Response: I apologize for this unclear phrasing. Considering that the observations was entirely visual, I have revised the text to "deformation" and have shown this effect in Fig 4B.

What do the authors mean by the term "bad air content"?

Response: As shown in Fig. 3B and Fig. 4B, it was histologically confirmed that there is an area with an poorly air space in the lungs of KO mice compared to WT.

6. Can the authors use their conditional allele to look at cell/tissue type roles of PKC delta?

Response: We have created this mouse to analyze the tissue-specific functions of PKC delta. Unfortunately, since the main researcher (YSN) has retired from research, no further experimental studies are possible. In the future, we believe that this conditional knockout mouse can be used for analysis of the tissue-specific function of PKC delta.

7. The top panels in Figure 5 can be omitted, as can the empty panel 4. Perhaps the authors could illustrate a smaller number of control and mutant embryos at higher magnification.

Response: We recreated Fig 6 as pointed out by Reviewer 2.

Minor points

8. The pictures of the heart in Fig3 would be improved if taken under buffer (PBS) to avoid reflection.

Response: Thank you for this suggestion. However, since the mice are no longer accessible, we are unable to provide improved images.

9. Data in Table 2 should be condensed.

Response: Table 2 has been renamed to Table 4, which presents the number of fetal sacs in each mother to demonstrate the effect on implantation of fertilized eggs. However, we condescend all individual mice into one group and presented the total number of fetal sacs to simplify the table.

10. Please spell out EVG and MT on first mention in the results.

Response: EVG and MT were defined in the "Histological Analysis" section of the revised Results.

Reviewer #3: In manuscript “PKCδ deficiency inhibits fetal development and is associated with heart elastic fiber

hyperplasia and lung inflammation in adult PKCδ knockout mice“ authors Niino et al., show how depletion of PKCδ (splicing variants I, II, IV, V, VI, and VII) affects fertility and development of mice. Authors demonstrate that PKCδ -/- mice are fertile but number of PKCδ-/- offspring was reduced. Furthermore, they observed defects in heart, lung, and spleen development. Presented manuscript thus points to protentional role of PKCδ in both development and in maintenance of homeostasis. Results are clearly described. I have only minor suggestions:

Response: Thank you very much for your careful review of our manuscript and for your helpful feedback.

In an effort to investigate the function of PKCδ, we designed PKCδ floxed mice with organ-and time-specific defects. However, unlike the results presented previously by Leitges et al., (17), Miyamoto et al., (18), and Mecklenbrauker et al., (19), PKCδ deficiency had a lethal effect on our knockout mice. Although some of the quantitative analyses are incomplete, we have chosen to publish the preliminary results in PLOS ONE, as we believe that they are of high importance in the field.

The phenotypes of the previously reported PKCδ KO mice, as well as those of the PKCδ KO mice produced in the current study, are described in the revised Discussion.

Below we have addressed each of your comment in a point-by-point manner. Please note that the numbers in the figures and tables have changed.

- Description of Fig1 should be contain the source references.

Response: Thank you for pointing this out. References have been added to the Fig. 1 legend.

- Authors analyse four PKCδ -/- mice, which show different results. It should be summarized in table and observed phenotype should be connected to sex and age of analysed mice.

Response: The phenotypes of the four PKCδ KO mice have been summarized in Table 3.

Attachment

Submitted filename: Response_to_Reviewers.docx

Decision Letter 1

Diego Fraidenraich

22 Apr 2021

PONE-D-20-38543R1

PKCδ deficiency inhibits fetal development and is associated with heart elastic fiber hyperplasia and lung inflammation in adult PKCδ knockout mice

PLOS ONE

Dear Dr. Gotoh,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Some problems with statistics and interpretations still remain. In addition, a few minor points need to be addressed.

Please submit your revised manuscript by 5/21/21. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Diego Fraidenraich

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

Some problems with statistics and interpretations still remain. In addition, a few minor points need to be addressed.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The efforts to include Kaplan Meier analysis and some statistical analysis is appreciated.

332- 339: this section is confusingly written and I think needs clarification. Are the authors saying the embryos were implanted at Mendelian ratios but that most KOs were dead at E11.5?

Table 2 still appears to lack stats. The data in this table are none-the-less interesting but the interpretation remains difficult. Het off spring die as readily as KO offspring from the KO crosses suggesting a rearing issue rather than a viability issue for the young. Drawing conclusions, clearly they KOs can produce offspring but are unable to rear the young. This is difficult to research and draw solid conclusions from which the authors acknowledge..

Reviewer #2: The manuscript has been revised and some of my earlier points answered. The following points should be addressed:

1. Lines 236-240 are not very conclusive or informative. These should be rephrased or deleted. The discussion of this point on line 424 may suffice.

2. Is there experimental justification to use the term hypertrophy on line 460 (see replies to previous comments)?

Reviewer #3: I have no other comments. All my questions and suggestions were successfully responded by authors.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jul 1;16(7):e0253912. doi: 10.1371/journal.pone.0253912.r004

Author response to Decision Letter 1


7 Jun 2021

Response to Editor Comments

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article's retracted status in the References list and also include a citation and full reference for the retraction notice.

Response: We checked the reference list of our paper. No literature was retracted.

Some problems with statistics and interpretations still remain. In addition, a few minor points need to be addressed.

Response to Reviewer's Comments

Reviewer #1: The efforts to include Kaplan Meier analysis and some statistical analysis is appreciated.

Response: We thank the reviewer for reading our revised manuscript in detail and helping us improve our paper. We have read your opinion carefully. Please find our response below.

Comment 1: 332- 339: this section is confusingly written and I think needs clarification. Are the authors saying the embryos were implanted at Mendelian ratios but that most KOs were dead at E11.5?

Response: In lines 305-325, we described that the proportion of the number of WT, He, and KO fetal sacs at E11.5 followed Mendelian laws. However, the proportion of surviving KO embryos (with heartbeat) was significantly lower than WT and He at E11.5. We apologize if this was not conveyed appropriately. We have changed the table (Table 3 in the revised manuscript) to include data showing the number of implantations and the survival rate. Additionally, we suggested that this phenomenon might occur due to a problem with KO development in the mother's body.

Comment 2: Table 2 still appears to lack stats. The data in this table are none-the-less interesting but the interpretation remains difficult. Het off spring die as readily as KO offspring from the KO crosses suggesting a rearing issue rather than a viability issue for the young. Drawing conclusions, clearly they KOs can produce offspring but are unable to rear the young. This is difficult to research and draw solid conclusions from which the authors acknowledge.

Response: We thank the reviewer for appreciating the data from Table 2. We agree with the reviewer that these data suggest possible childcare issues. Since Table 2 does not have enough data to analyze and draw statistically significant conclusions, we have removed Table 2 and its description from the revised manuscript.

Reviewer #2: The manuscript has been revised and some of my earlier points answered. The following points should be addressed:

Response: We thank the reviewer for reading our revised manuscript in detail and helping us improve our paper. We have read your opinion carefully. Please find our response below.

Comment 1. Lines 236-240 are not very conclusive or informative. These should be rephrased or deleted. The discussion of this point on line 424 may suffice.

Response: We thank the reviewer for the comment. Since Table 2 did not have enough data to analyze and draw statistically significant conclusions, we have removed Table 2 and its description from the revised manuscript.

Comment 2. Is there experimental justification to use the term hypertrophy on line 460 (see replies to previous comments)?

Response: We could not provide additional experimental data showing that the enlarged heart in a PKCδ KO mouse corresponds to cardiac hypertrophy. Therefore, we deleted the word “hypertrophy” at all relevant instances and instead rewrote all statements signifying that the heart of the PKCδ KO mouse was "enlarged".

Reviewer #3: I have no other comments. All my questions and suggestions were successfully responded by authors.

Response: We thank the reviewer for reading our treatise in detail and for the constructive feedback.

Attachment

Submitted filename: Responses_Letter.docx

Decision Letter 2

Diego Fraidenraich

16 Jun 2021

PKCδ deficiency inhibits fetal development and is associated with heart elastic fiber hyperplasia and lung inflammation in adult PKCδ knockout mice

PONE-D-20-38543R2

Dear Dr. Gotoh,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Diego Fraidenraich

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Diego Fraidenraich

23 Jun 2021

PONE-D-20-38543R2

PKCδ deficiency inhibits fetal development and is associated with heart elastic fiber hyperplasia and lung inflammation in adult PKCδ knockout mice

Dear Dr. Gotoh:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Diego Fraidenraich

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Raw images. Original gel images of Fig 2B-1 (DIG), Fig 2B-2 (EtBr) and Fig 2C.

    (PDF)

    Attachment

    Submitted filename: Response_to_Reviewers.docx

    Attachment

    Submitted filename: Responses_Letter.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES